temozolomide has been researched along with 5-(3-methyl-1-triazeno)imidazole-4-carboxamide in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, AS; Deans, B; Denny, BJ; Hartley, JA; Stevens, MF; Tisdale, MJ; Wheelhouse, RT | 1 |
| Koch, M; Koomen, GJ; Wanner, MJ | 1 |
| Gescher, A; Quarterman, CP; Slack, JA; Tsang, LL | 1 |
| Bonmassar, E; D'Atri, S; Gilberti, S; Graziani, G; Lacal, PM; Tentori, L | 1 |
| Denny, BJ; Slack, JA; Stevens, MF; Tsang, LL; Wheelhouse, RT | 1 |
| Ames, MM; Reid, JM; Rubin, J; Stevens, DC | 1 |
| Alton, K; Baker, SD; Batra, V; Cutler, D; Donehower, RC; Dugan, M; Grochow, LB; Reidenberg, P; Rowinsky, EK; Sartorius, SE; Statkevich, P; Wirth, M | 1 |
| Alton, KB; Blumenkrantz, N; Chowdhury, SK; Laudicina, D; Wirth, M | 1 |
| Brent, TP; Friedman, HS; Houghton, PJ; Kirstein, MN; Middlemas, DS; Poquette, C; Stewart, CF | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Chu, J; Gallo, JM; Li, S; Ma, J; Pulfer, S; Reed, K | 1 |
| Fouladi, M; Gajjar, A; Heideman, RL; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF; Wilkinson, M | 1 |
| Baker, SD; Batra, VK; Cutler, DL; Donehower, RC; Rudek, MA; Statkevich, P | 1 |
| Batra, VK; Patrick, J; Reyderman, L; Statkevich, P; Thonoor, CM; Wirth, M | 1 |
| Freeman, BB; Gajjar, A; Iacono, LC; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF | 1 |
| Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K | 1 |
| Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ | 1 |
5 trial(s) available for temozolomide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide
| Article | Year |
|---|---|
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Topics: Adult; Alkylating Agents; Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; Dacarbazine; Half-Life; Humans; Metabolic Clearance Rate; Neoplasms; Regression Analysis; Temozolomide | 1997 |
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Topics: Absorption; Administration, Oral; Adult; Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Blood Proteins; Carbon Radioisotopes; Dacarbazine; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Temozolomide | 1999 |
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Availability; Body Surface Area; Brain Neoplasms; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dacarbazine; Female; Humans; Infant; Linear Models; Male; Metabolic Clearance Rate; Reproducibility of Results; Temozolomide | 2003 |
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Alkylating Agents; Area Under Curve; Bilirubin; Capsules; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Temozolomide; Thrombocytopenia; Tissue Distribution; Treatment Failure | 2004 |
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Central Nervous System Neoplasms; Child; Dacarbazine; Humans; Infant; Metabolic Clearance Rate; Monte Carlo Method; Temozolomide | 2005 |
12 other study(ies) available for temozolomide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide
| Article | Year |
|---|---|
Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cell Survival; Dacarbazine; DNA; DNA Primers; Heterocyclic Compounds; Mice; Models, Molecular; Molecular Probes; Molecular Sequence Data; Temozolomide; Tumor Cells, Cultured | 1995 |
Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the antiresistance drug O(6)-benzylguanine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Diazomethane; DNA Methylation; Drug Resistance, Neoplasm; Guanine; Humans; Hydrolysis; Prodrugs; Temozolomide; Triazenes | 2004 |
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dacarbazine; Lymphoma; Mice; Prodrugs; Temozolomide; Tumor Cells, Cultured | 1991 |
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Gene Expression; Humans; Leukemia; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; RNA, Messenger; Temozolomide; Tumor Cells, Cultured | 1995 |
NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.
Topics: Antineoplastic Agents; Calorimetry; Dacarbazine; DNA; Drug Stability; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Molecular Conformation; Molecular Structure; Nucleic Acid Conformation; Temozolomide | 1994 |
An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
Topics: Animals; Antineoplastic Agents, Alkylating; Calibration; Chromatography, High Pressure Liquid; Dacarbazine; Dogs; Female; Male; Mass Spectrometry; Quality Control; Rats; Reproducibility of Results; Temozolomide | 1999 |
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Carrier Proteins; Cell Division; Child; Dacarbazine; DNA Repair; DNA-Binding Proteins; Female; Humans; Mice; Mice, Inbred CBA; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Neuroblastoma; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Proto-Oncogene Proteins; Rhabdomyosarcoma; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cyclohexanes; Dacarbazine; Dialysis Solutions; Drug Interactions; Humans; Male; Microdialysis; Neoplasms, Experimental; O-(Chloroacetylcarbamoyl)fumagillol; Rats; Rats, Nude; Sesquiterpenes; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Disposition and pharmacokinetics of temozolomide in rat.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Autoradiography; Brain; Carbon Radioisotopes; Dacarbazine; Female; Injections, Intravenous; Male; Radiopharmaceuticals; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Temozolomide; Tissue Distribution | 2004 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; White People | 2007 |
Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
Topics: Antineoplastic Agents, Alkylating; Cholesterol; Dacarbazine; Dimyristoylphosphatidylcholine; Drug Interactions; Glioblastoma; Humans; Membranes, Artificial; Temozolomide | 2019 |